Editorial review: osvilt.com Editorial Team
Last reviewed: July 16, 2026
How we reviewed this page: We checked current regulator guidance, product information and clinical guidance. Brand formulas and approvals vary by country, so readers should verify the exact local label.
This article is educational and does not replace individual care. Read our Medical Review Policy and Medical Disclaimer.
Ganaton and Motilium can both appear in discussions of upper-digestive symptoms, but they are different medicines. Ganaton contains itopride, a prokinetic used in some countries for symptoms associated with delayed gastric motility or functional dyspepsia. Motilium contains domperidone, an antiemetic/prokinetic with important heart-rhythm restrictions.
Bottom line: choose by the diagnosed problem, not by which brand seems “stronger.” In the EU, domperidone is restricted to nausea and vomiting, at the lowest effective dose for the shortest duration; itopride evidence for functional dyspepsia is limited and availability varies.
Ganaton vs Motilium at a glance
| Point | Ganaton | Motilium |
|---|---|---|
| Active ingredient | Itopride hydrochloride | Domperidone |
| Typical role | Dyspeptic symptoms related to motility in markets where approved. | Relief of nausea and vomiting where approved. |
| Evidence | Some benefit for selected functional dyspepsia symptoms; guideline certainty is low. | Regulators accept a limited nausea/vomiting role but restrict dose, duration and patients. |
| Major concern | Not a substitute for diagnosing persistent symptoms; local contraindications/interactions apply. | QT prolongation, ventricular arrhythmia and sudden cardiac death in susceptible people. |
| Interchangeable? | No. The same symptom can have different causes, and the drugs have different risk profiles. | |
How strong is the evidence?
The British Society of Gastroenterology guideline says some prokinetics may help functional dyspepsia, but efficacy varies by drug and the evidence for itopride is low quality. The guideline also notes that readily available prokinetics have safety or evidence limitations. This supports a cautious, diagnosis-first approach rather than routine long-term use.
For domperidone, the EMA review concluded that benefits continue to outweigh risks only for relief of nausea and vomiting under restrictions. It found insufficient evidence for uses such as bloating and heartburn.
Which symptom are you trying to treat?
- Nausea or vomiting: the cause and dehydration risk matter. Domperidone may be considered only when appropriate and locally authorized.
- Early fullness, post-meal heaviness or upper-abdominal bloating: these may fit functional dyspepsia, but ulcers, reflux, medication effects and other causes may need assessment.
- Heartburn: neither drug should be chosen as a generic acid-reflux treatment without evaluation.
- Persistent symptoms: treatment should not delay testing for H. pylori, anemia, obstruction or another cause when clinically indicated.
Domperidone cardiac restrictions and other safety points
The EMA recommends oral domperidone 10 mg up to three times daily for adults and eligible adolescents, generally for no longer than one week. This is regulator context, not a personal dose recommendation. Domperidone is contraindicated with impaired cardiac conduction, underlying cardiac disease such as heart failure, severe liver impairment, QT-prolonging medicines or potent CYP3A4 inhibitors. Risk is higher with larger doses, longer use and in older adults.
Before either medicine, provide a pharmacist or clinician with your full medicine list. Do not switch, combine or extend treatment because symptoms return.
Seek urgent care for fainting, palpitations, chest pain, vomiting blood, black stools, severe or localized abdominal pain, inability to keep fluids down, marked dehydration or suspected obstruction. Arrange medical review for progressive swallowing trouble, anemia, unexplained weight loss or recurrent vomiting.
FAQ
Is Ganaton safer than Motilium?
It avoids domperidone’s specific regulatory cardiac restrictions, but it is not risk-free and may not match the same indication. Safety depends on the patient and the reason for treatment.
Can Ganaton replace Motilium for nausea?
Not automatically. Nausea is not the same as functional dyspepsia, and the drugs are not approved for identical uses in every country.
Can Motilium be used for bloating?
The EMA found insufficient evidence to support domperidone for bloating and heartburn. Persistent bloating deserves a cause-based plan.
Sources reviewed
We prioritize regulators, official product information and clinical guidelines. External sources were checked on July 16, 2026.
- EMA: Domperidone-containing medicines referral
- UK MHRA: Domperidone risks of cardiac side effects
- British Society of Gastroenterology: Functional dyspepsia guideline
- Ganaton: product information leaflet
